Compare ACADIA Pharmaceuticals Inc. (ACAD) vs iShares 0 3 Month Treasury Bond ETF (SGOV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs iShares 0 3 Month Treasury Bond ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.44 (market cap $5.07B), while iShares 0 3 Month Treasury Bond ETF trades at $100.52. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, iShares 0 3 Month Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| ACAD | SGOV | |
|---|---|---|
Market Cap | $5.07B | — |
Sector | Health | Fixed Income |
52-Week High | $29.41 | $100.74 |
52-Week Low | $20.06 | $100.28 |
Enterprise Value | $4.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.39, up 0.62% on the day, with strong earnings momentum after Q2 2026 results beat expectations. The stock shows bullish technical signals from moving averages, though oscillators suggest potential overbought conditions. Revenue growth has been robust, rising from $517M in 2022 to $1.07B in 2025, with net income turning positive and margins expanding significantly. Recent news highlights FDA Fast Track designation for remlifanserin and raised 2026 revenue guidance.
Outlook remains positive driven by product sales growth and pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Analyst consensus is strongly bullish with a $33.89 price target, indicating ~15% upside. Investment appeal hinges on execution of commercial strategy and successful drug development.
SGOV (iShares 0-3 Month Treasury Bond ETF) trades at $100.51 with minimal daily movement, reflecting its role as a stable cash alternative. The ETF maintains a bearish technical signal from moving averages while oscillators show neutral momentum. Recent institutional activity includes mixed positioning changes, with Bank of America increasing holdings while Deane Retirement Strategies significantly reduced exposure. The fund offers monthly distributions with a current yield around 3.8%, attracting defensive positioning amid market volatility.
SGOV provides principal protection and liquidity with minimal interest rate risk, making it suitable for conservative investors seeking yield above traditional savings. Key risks include Federal Reserve policy changes impacting short-term rates and inflation dynamics affecting real returns. The ETF's stability and monthly income stream offer defensive characteristics during economic uncertainty, though limited upside potential compared to equity investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About iShares 0 3 Month Treasury Bond ETF
SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →
